314O_PR Second-line afatinib vs methotrexate (MTX) in patients (pts) with recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC): subgroup/biomarker analysis of LUX-head and neck 1 (LUX-H&N1)
Tahara M, Cohen E, Haddad R, Fayette J, Licitra L, Clement P, Vermorken J, Gauler T, Cupissol D, Grau J, Guigay J, del Campo J, Okami K, Takahashi S, Burtness B, Cong X, Gibson N, Solca F, Ehrnrooth E, Machiels J. 314O_PR Second-line afatinib vs methotrexate (MTX) in patients (pts) with recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC): subgroup/biomarker analysis of LUX-head and neck 1 (LUX-H&N1). Annals Of Oncology 2015, 26: ix93. DOI: 10.1093/annonc/mdv527.01.Peer-Reviewed Original ResearchBiomarker analysis in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients (pts) treated with second-line afatinib versus methotrexate (MTX): LUX-Head & Neck 1 (LUX-H&N1).
Cohen E, Licitra L, Fayette J, Gauler T, Clement P, Grau J, Del Campo J, Mailliez A, Haddad R, Vermorken J, Tahara M, Guigay J, Geoffrois L, Merlano M, Dupuis N, Burtness B, Gibson N, Solca F, Ehrnrooth E, Machiels J. Biomarker analysis in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients (pts) treated with second-line afatinib versus methotrexate (MTX): LUX-Head & Neck 1 (LUX-H&N1). Journal Of Clinical Oncology 2015, 33: 6023-6023. DOI: 10.1200/jco.2015.33.15_suppl.6023.Peer-Reviewed Original Research